WO2016149558A3 - Compositions de vaccins et d'adjuvants et méthodes de traitement d'infections urinaires - Google Patents

Compositions de vaccins et d'adjuvants et méthodes de traitement d'infections urinaires Download PDF

Info

Publication number
WO2016149558A3
WO2016149558A3 PCT/US2016/022977 US2016022977W WO2016149558A3 WO 2016149558 A3 WO2016149558 A3 WO 2016149558A3 US 2016022977 W US2016022977 W US 2016022977W WO 2016149558 A3 WO2016149558 A3 WO 2016149558A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
urinary tract
tract infections
compositions
coli
Prior art date
Application number
PCT/US2016/022977
Other languages
English (en)
Other versions
WO2016149558A2 (fr
Inventor
Gary Eldridge
Steven M. Martin
Original Assignee
Sequoia Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/660,523 external-priority patent/US9149521B2/en
Priority claimed from US14/800,003 external-priority patent/US9415097B2/en
Application filed by Sequoia Sciences, Inc. filed Critical Sequoia Sciences, Inc.
Priority to EP16765794.9A priority Critical patent/EP3270963A4/fr
Priority to CN201680016475.7A priority patent/CN107530418A/zh
Publication of WO2016149558A2 publication Critical patent/WO2016149558A2/fr
Publication of WO2016149558A3 publication Critical patent/WO2016149558A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de nouvelles compositions et formulations d'adjuvants présentant une excellente stabilité en milieu réfrigéré et à température ambiante jusqu'à environ 37 °C, et pouvant être produites à des coûts remarquablement bas. La présente invention décrit de nouvelles compositions et formulations de vaccins pour traiter et prévenir des infections urinaires provoquées par des bactéries à Gram négatif, notamment Escherichia coli et E. coli.multirésistants aux médicaments. La présente invention concerne en outre des méthodes d'administration desdites nouvelles compositions et formulations de vaccins et des méthodes thérapeutiques pour prévenir et traiter des infections urinaires provoquées par des bactéries à Gram négatif, notamment E. coli et des E. coli multirésistantes aux médicaments.
PCT/US2016/022977 2015-03-17 2016-03-17 Compositions de vaccins et d'adjuvants et méthodes de traitement d'infections urinaires WO2016149558A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP16765794.9A EP3270963A4 (fr) 2015-03-17 2016-03-17 Compositions de vaccins et d'adjuvants et méthodes de traitement d'infections urinaires
CN201680016475.7A CN107530418A (zh) 2015-03-17 2016-03-17 疫苗与佐剂的组合物以及治疗尿路感染的方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14/660,523 US9149521B2 (en) 2013-09-25 2015-03-17 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US14/660,523 2015-03-17
US201562135092P 2015-03-18 2015-03-18
US62/135,092 2015-03-18
US14/800,003 US9415097B2 (en) 2013-09-25 2015-07-15 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US14/800,003 2015-07-15

Publications (2)

Publication Number Publication Date
WO2016149558A2 WO2016149558A2 (fr) 2016-09-22
WO2016149558A3 true WO2016149558A3 (fr) 2017-03-23

Family

ID=56919421

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2016/022711 WO2016149417A1 (fr) 2015-03-17 2016-03-16 Compositions de vaccins, adjuvants et méthodes de traitement d'infections urinaires
PCT/US2016/022977 WO2016149558A2 (fr) 2015-03-17 2016-03-17 Compositions de vaccins et d'adjuvants et méthodes de traitement d'infections urinaires

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2016/022711 WO2016149417A1 (fr) 2015-03-17 2016-03-16 Compositions de vaccins, adjuvants et méthodes de traitement d'infections urinaires

Country Status (3)

Country Link
EP (2) EP3270962A4 (fr)
CN (2) CN107405395A (fr)
WO (2) WO2016149417A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094A (en) * 1988-06-29 1990-03-27 Ribi Immunochem Research, Inc. Modified lipopolysaccharides and process of preparation
US6630161B1 (en) * 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
US20050196408A1 (en) * 2000-08-18 2005-09-08 Medimmune, Inc. Method of administering FimH protein as a vaccine for urinary tract infections
US20120164176A1 (en) * 2009-07-15 2012-06-28 Kurt Swanson Rsv f protein compositions amd methods for making same
US20150017191A1 (en) * 2012-02-07 2015-01-15 Infectious Disease Research Institute Adjuvant formulations comprising tlr4 agonists and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001297896A1 (en) * 2000-12-08 2003-01-02 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
ES2673046T3 (es) * 2006-09-26 2018-06-19 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2010124085A2 (fr) * 2009-04-23 2010-10-28 Cornell University Compositions et méthodes pour prévenir et traiter une maladie utérine
WO2011005769A1 (fr) * 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Procédés de préparation de vésicules et formulations obtenues à partir de celles-ci
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9017698B2 (en) * 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094A (en) * 1988-06-29 1990-03-27 Ribi Immunochem Research, Inc. Modified lipopolysaccharides and process of preparation
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US6630161B1 (en) * 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
US20050196408A1 (en) * 2000-08-18 2005-09-08 Medimmune, Inc. Method of administering FimH protein as a vaccine for urinary tract infections
US20120164176A1 (en) * 2009-07-15 2012-06-28 Kurt Swanson Rsv f protein compositions amd methods for making same
US20150017191A1 (en) * 2012-02-07 2015-01-15 Infectious Disease Research Institute Adjuvant formulations comprising tlr4 agonists and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOX ET AL.: "Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, vol. 19, no. 10, 2012, pages 1633 - 1640, XP055286524 *
JOHNSON ET AL.: "3- O -Desacyl Monophosphoryl Lipid A Derivatives: Synthesis and Immunostimulant Activities", J. MED. CHEM., vol. 42, 1999, pages 4640 - 4649, XP002186005 *
See also references of EP3270963A4 *

Also Published As

Publication number Publication date
WO2016149558A2 (fr) 2016-09-22
EP3270962A4 (fr) 2018-08-22
EP3270962A1 (fr) 2018-01-24
CN107405395A (zh) 2017-11-28
EP3270963A2 (fr) 2018-01-24
WO2016149417A1 (fr) 2016-09-22
EP3270963A4 (fr) 2018-08-22
CN107530418A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
WO2015044886A3 (fr) Compositions de vaccins, adjuvants et procédés pour le traitement d'infections urinaires
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
WO2015003816A3 (fr) Cystobactamides
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
WO2015181356A8 (fr) Composition vaccinale contre une infection par streptococcus suis
WO2018208985A3 (fr) Composés antibactériens
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
EP3474861A4 (fr) Composés comprenant des hmos pour la prévention et/ou le traitement d'infections virales et/ou bactériennes.
CA3010327A1 (fr) Pyrimidines a substitution aryle a utiliser dans une infection par le virus de la grippe
WO2016100578A3 (fr) Polymyxines antimicrobiennes pour le traitement d'infections bactériennes
WO2015161243A3 (fr) Bêta-lactamases présentant des propriétés améliorées pour traitement
WO2015112980A3 (fr) Peptides antimicrobiens du type dermaseptines et piscidines
WO2016142445A3 (fr) Méthode de traitement d'une infection bactérienne
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
PH12016501988A1 (en) Antibacterial compounds
ZA202002093B (en) Antibacterial compounds
EP4268897A3 (fr) Composés de minocycline pour la défense biologique
MX2017009094A (es) Derivado de polimixina y usos del mismo.
MX2019005751A (es) Tratamiento de enfermedades e infecciones de las vias respiratorias con composiciones de acido ascorbico.
WO2018109042A3 (fr) Peptides antimicrobiens
WO2016057630A3 (fr) Procédé de traitement d'infections au moyen de dérivés de siloxane
WO2015130547A8 (fr) Compositions de composés de guanidine bis-cyclique, méthodes d'utilisation et de traitement associées
EP3292872A4 (fr) Composition pour le traitement ou la prévention de maladies infectieuses inflammatoires ou composition pour l'amélioration de l'immunité comprenant de la tryptophanyl-arnt synthétase en tant que principe actif
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
MX2018011095A (es) Compuestos de carbapenem.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16765794

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2016765794

Country of ref document: EP